CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues
Revenues	$ 2,153	$ 1,944
Expenses
Selling, general and administrative	794	725
Research and development	151	143
Amortization of intangible assets	274	273
Asset impairments	1	13
Restructuring, integration and separation costs	12	10
Other expense, net	0	23
Total expenses	1,872	1,769
Operating income	281	175
Interest income	9	6
Interest expense	(355)	(307)
Gain on extinguishment of debt	11	0
Foreign exchange and other	(15)	(10)
Loss before income taxes	(69)	(136)
Provision for income taxes	(8)	(73)
Net loss	(77)	(209)
Net loss attributable to noncontrolling interest	13	8
Net loss attributable to Bausch Health Companies Inc.	$ (64)	$ (201)
Basic loss per share attributable to Bausch Health Companies Inc. (in usd per share)	$ (0.17)	$ (0.55)
Diluted loss per share attributable to Bausch Health Companies Inc. (in usd per share)	$ (0.17)	$ (0.55)
Basic weighted-average common shares (in shares)	366,800	363,300
Diluted weighted-average common shares (in shares)	366,800	363,300
Product sales
Revenues
Revenues	$ 2,129	$ 1,922
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	628	572
Other revenues
Revenues
Revenues	24	22
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	$ 12	$ 10